Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Olanzapine vs risperidone in the management of schizophrenia: A randomized double-blind trial in Australia and New Zealand
Schizophrenia Research, Volume 61, No. 2-3, Year 2003
Notification
URL copied to clipboard!
Description
Improved drug therapy for schizophrenia may represent the best strategy for reducing the costs of schizophrenia and the recurrent chronic course of the disease. Olanzapine and risperidone are atypical antipsychotic agents developed to meet this need. We report a multicenter, double-blind, parallel, 30-week study designed to compare the efficacy, safety, and associated resource use for olanzapine and risperidone in Australia and New Zealand. The study sample consisted of 65 patients who met DSM-IV criteria for schizophrenia, schizoaffective disorder, or schizophreniform disorder. Olanzapine-treated patients showed a significantly greater reduction in Positive and Negative Syndrome Scale (PANSS) total, Brief Psychiatric Rating Scale (BPRS) total, and PANSS General Psychopathology scores at endpoint compared to the risperidone-treated patients. Response rates through 30 weeks showed a significantly greater proportion of olanzapine-treated patients had achieved a 20% or greater improvement in their PANSS total score compared to risperidone-treated patients. Olanzapine and risperidone were equivalent in their improvement of PANSS positive and negative scores and Clinical Global Impression-Severity of Illness scale (CGI-S) at endpoint. Using generic and disease-specific measures of quality of life, olanzapine-treated patients showed significant within-group improvement in most measures, and significant differences were observed in favor of olanzapine over risperidone in Quality of Life Scale (QLS) Intrapsychic Foundation and Medical Outcomes Study Short Form 36-item instrument (SF-36) Role Functioning Limitations - Emotional subscale scores. Despite the relatively small sample size, our study suggests that olanzapine has a superior risk:benefit profile compared to risperidone. © 2002 Elsevier Science B.V. All rights reserved.
Authors & Co-Authors
Gureje, Oye
Nigeria, Ibadan
University College Hospital, Ibadan
Miles, Wayne
New Zealand, Auckland
Mental Health Services
Keks, Nicholas
Australia, Clayton
Monash University
Grainger, David
Unknown Affiliation
Lambert, Tim J.R.
Australia, Melbourne
University of Melbourne
McGrath, John Joseph
Australia, Wacol
Wolston Park Hospital
Tran, Pierre
United States, Indianapolis
Eli Lilly and Company
Catts, Stanley Victor
Australia, Sydney
Unsw Sydney
Fraser, Allen
New Zealand, Auckland
School of Medicine
Hustig, Harry H.
Australia, Adelaide
The University of Adelaide
Andersen, Scott
United States, Indianapolis
Eli Lilly and Company
Crawford, Ann Marie
United States, Indianapolis
Eli Lilly and Company
Statistics
Citations: 78
Authors: 12
Affiliations: 9
Identifiers
Doi:
10.1016/S0920-9964(02)00226-8
ISSN:
09209964
Research Areas
Disability
Mental Health